Vaccine formulation design: challenges and opportunities
RSC Pharmaceutics,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 1, 2025
A
review
on
vaccines
considering
recent
advances
in
design
and
development.
Язык: Английский
Virus-like particles in poultry disease: an approach to effective and safe vaccination
Frontiers in Veterinary Science,
Год журнала:
2024,
Номер
11
Опубликована: Сен. 9, 2024
The
poultry
industry,
a
cornerstone
of
global
food
security,
faces
dynamic
challenges
exacerbated
by
viral
diseases.
This
review
traces
the
trajectory
vaccination,
evolving
from
traditional
methods
to
forefront
innovation
Virus-Like
Particle
(VLP)
vaccines.
Vaccination
has
been
pivotal
in
disease
control,
but
vaccines
exhibit
some
limitations.
examines
emergence
VLPs
as
game-changer
vaccination.
VLPs,
mimicking
viruses
without
replication,
offer
safer,
targeted
alternative
with
enhanced
immunogenicity.
narrative
encompasses
VLP
design
principles,
production
methods,
immunogenicity,
and
efficacy
against
major
viruses.
Challenges
prospects
are
explored,
presenting
transformative
technique
control.
Understanding
their
potential
empowers
industry
stakeholders
navigate
health
management
precision,
promising
improved
welfare,
reduced
economic
losses,
heightened
safety.
Язык: Английский
CRISPR-Cas based genome editing for eradication of human viruses
Dharmisha Solanki,
Karan Murjani,
Vijai Singh
и другие.
Progress in molecular biology and translational science,
Год журнала:
2024,
Номер
unknown, С. 43 - 58
Опубликована: Янв. 1, 2024
Язык: Английский
A single dose of an ALVAC vector-based RABV virus-like particle candidate vaccine induces a potent immune response in mice, cats and dogs
Emerging Microbes & Infections,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 19, 2024
Rabies,
caused
by
the
Rabies
virus
(RABV),
is
a
highly
fatal
zoonotic
disease.
Existing
rabies
vaccines
have
demonstrated
good
immune
efficacy,
but
complexity
of
immunization
procedures
and
high
cost
has
impeded
elimination
RABV,
particularly
in
post-COVID-19
era.
There
pressing
need
for
safer
more
effective
that
streamline
vaccination
protocols
reduce
expense.
To
meet
this
need,
we
developed
potential
vaccine
candidate
called
ALVAC-RABV-VLP,
utilizing
CRISPR/Cas9
gene
editing
technology.
This
employs
canarypox
vector
(ALVAC)
to
generate
RABV
virus-like
particles
(VLPs).
In
mice,
single
dose
ALVAC-RABV-VLP
effectively
activated
dendritic
cells
(DCs),
follicular
helper
T
(Tfh),
germinal
center
(GC)/plasma
cell
axis,
resulting
durable
humoral
responses.
The
survival
rate
mice
challenged
with
lethal
was
100%.
Similarly,
dogs
cats,
elicited
stronger
longer-lasting
antibody
response.
induced
superior
cellular
immunity
both
beagles
compared
commercial
inactivated
vaccine.
conclusion,
robust
protective
responses
offering
novel,
cost-effective,
efficient,
promising
approach
herd
prevention
rabies.
Язык: Английский
Dimming the corona: studying SARS-coronavirus-2 at reduced biocontainment level using replicons and virus-like particles
mBio,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 12, 2024
The
coronavirus-induced
disease
19
(COVID-19)
pandemic,
caused
by
severe
acute
respiratory
syndrome
coronavirus-2
(SARS-CoV-2)
infections,
has
had
a
devastating
impact
on
millions
of
lives
globally,
with
mortality
rates
and
catastrophic
social
implications.
Developing
tools
for
effective
vaccine
strategies
platforms
is
essential
controlling
preventing
the
recurrence
such
pandemics.
Moreover,
molecular
virology
that
facilitate
study
viral
pathogens,
mutations,
interactions
various
host
proteins
are
essential.
Viral
replicon-
virus-like
particle
(VLP)-based
systems
excellent
examples
tools.
This
review
outlines
importance,
advantages,
disadvantages
both
VLP-based
have
been
developed
SARS-CoV-2
helped
scientific
community
in
dimming
intensity
COVID-19
pandemic.
Язык: Английский